Important information
CDC guidance now recommends that moderately to severely immunocompromised patients receive an additional (third) dose of an mRNA COVID-19 vaccine (Pfizer-BioNTech or Moderna). If you have undergone anti-cancer therapy in the past year, you are within 1 year of stem cell transplantation or are receiving medications that suppress your immune system, you are encouraged to obtain a third COVID-19 vaccination shot. If you received the Johnson & Johnson single dose vaccination, please consult your doctor regarding next steps. Find vaccination locations here.
If you are within 100 days of a stem cell transplantation, we do not recommend that you receive a COVID-19 vaccination until you are cleared by your care team to do so. If you are currently on a clinical research trial, please contact your clinical research team for more guidance. Please contact your care coordinator if you have additional questions about receiving an additional COVID-19 vaccine shot.
The HCA Midwest Health clinical research program supports overall patient care by offering another therapeutic option through clinical trials. These clinical studies are available through Sarah Cannon Research Institute and various pharmaceutical and CRO partners.
AML 52: Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine VS Venetoclax _ Aza in Newly Diagnosed AML Unfit for Intensive Chemo. PI: Suman Kambhampati, MD
Facility: Research Medical Center
AML 58: Tamibarotene in Combination with Venetoclax and Azacitidine in Previously Untreated Adult Patients Selected for RARA-positive AML Who Are Ineligible for Standard Induction Therapy. PI: Suman Kambhampati, MD
Facility: Research Medical Center
AML 59: A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine versus Physician’s Choice of Venetoclax in Combination with Azacitidine or Intensive Chemotherapy in Previously Untreated Patients with TP53 Mutant Acute Myeloid Leukemia. PI: Suman Kambhampati, MD
Facility: Research Medical Center
AML 64: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy. PI: Suman Kambhampati, MD
Facility: Research Medical Center
CLL 51: A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-322). PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center
LYM 155: Single Arm, Phase II Study of Acalabrutinib as Post-Autologous Blood or Marrow Transplant (BMT) Maintenance Therapy in Subjects with Mantle Cell Lymphoma. PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center
LYM 182: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL). PI: Suman Kambhampati, MD.
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center
MDS 31: A Phase ½ Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of Nuclear Export (SINE) Compound Eltanexor (KPT-8602) in Patients with Newly Diagnosed and Relapsed/Refractory Cancer Indications. PI: Suman Kambhampati, MD
Facility: Research Medical Center
MM 109: A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients with Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant. PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center
MM 136: A Phase 3, two-stage, randomized, multicenter, open label study comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) vs Daratumumab, Bortezomib and Dexamethasone (DVD) in subjects with relapsed or refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM). PI: Suman Kambhampati, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center
KC-BRE-002: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib. PI: Aruna Rokkam, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center
Catalyst:
Evaluates the safety and effectiveness of the Amulet LAA Occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. Principal Investigator: Dr. James Marcum
Facility: Overland Park Regional Medical Center, Research Medical Center
Champion AF:
To determine if left atrial appendage closure with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants in patients with non-valvular atrial fibrillation. Principal Investigator: Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center, Research Medical Center
Define AF:
Aims to improve the understanding of how data from the Reveal LINQ™ or LINQ II™ insertable cardiac monitor (ICM) can be used to guide the management of Afib. Principal Investigator: Dr. Dhanunjaya Lakkireddy
Facility: Centerpoint, Research Medical Center, Overland Park Regional Medical Center, Menorah Medical Center
Leadless II:
Designed to confirm the safety and effectiveness of the Aveir LP System in a subject population indicated for a single chamber pacemaker. Principle Investigator: Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center
LUX-Dx PERFORM:
To characterize the utilization of the remote programming feature of the Boston Scientific (BSC) Insertable Cardiac Monitor (ICM) device. The study will also collect data to characterize the performance of arrhythmia detection. Finally, data collected will be used to analyze and characterize the ICM system-related safety events. Principal Investigator: Dr. Scott Koerber
Facility: Centerpoint, Research Medical Center, Overland Park Regional Medical Center
RELIEVE-HF:
To provide reasonable assurance of safety and effectiveness of the V-Wave Interatrial Shunt System to improve clinical outcomes in a certain high-risk subset of symptomatic patients suffering from HF. Principal Investigator: Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center, Research Medical Center
Solve CRT:
To study the safety and efficacy of the WiSE-CRT System for Cardiac Re-synchronization Therapy. Principal Investigator: Dr. Dhanunjaya Lakkireddy
Facility: Overland Park Regional Medical Center, Research Medical Center
KC-GI-001: A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT). PI: Mohammad Mozayen, MB
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center
There are currently no research trials.
KC-GYN-002: A phase 3, Randomized, double-blind, placebo-controlled, Multi-center study of Upifitamab Rilsodotin as post-platinum maintenance therapy for participants with Platinum-sensitive recurrent ovarian cancer (UP-NEXT). PI: K. Shawn Lybarger, DO
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center
There are currently no research trials.
KC-CNS-001: A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma. PI: Amandeep Kalra, MD
Facility: Research Medical Center
KC-CNS-002: A Parallel-group, Two-staged, Phase 2/3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants with progressive NF2 mutated Meningiomas. PI: Amandeep Kalra, MD
Facility: Research Medical Center
KC-LUN-001: A phase I/III, Randomized, Double-blind, placebo-controlled studyof Atezoluzumab and Tiragolumab compared with Durvalumab in patients with unresectable stage III Non-small cell lung cancer who have not progress after concurrent platinum-based chemoradiation. PI: Joseph Stilwill, MD
Facility: Centerpoint Medical Center, Menorah Medical Center, Research Medical Center
There are currently no research trials.